Xiaowei Qi

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Transcription Factor

Sentinel Lymph Node

Neoadjuvant Chemotherapy

Top Venues

Cancer innovation

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Cheng Wang, Qiyun Shi, Guozhi Zhang, Xiujuan Wu, Wenting Yan, Andi Wan, Siyi Xiong, Long Yuan, Hao Tian, Dandan Ma, Jun Jiang, Xiaowei Qi, Yi Zhang
Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer. The oncologist 29 (5) (2024)
Cheng Wang, Qiyun Shi, Guozhi Zhang, Xiujuan Wu, Wenting Yan, Andi Wan, Siyi Xiong, Long Yuan, Hao Tian, Dandan Ma, Jun Jiang, Xiaowei Qi, Yi Zhang
Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer. The oncologist (2024)
Cheng Wang, Qiyun Shi, Guozhi Zhang, Xiujuan Wu, Wenting Yan, Andi Wan, Siyi Xiong, Long Yuan, Hao Tian, Dandan Ma, Jun Jiang, Xiaowei Qi, Yi Zhang
Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer. The oncologist 29 (5) (2024)
Cheng Wang, Qiyun Shi, Guozhi Zhang, Xiujuan Wu, Wenting Yan, Andi Wan, Siyi Xiong, Long Yuan, Hao Tian, Dandan Ma, Jun Jiang, Xiaowei Qi, Yi Zhang
Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer. The oncologist 29 (5) (2024)
Cheng Wang, Long Yuan, Xiujuan Wu, Yan Wang, Hao Tian, Guozhi Zhang, Andi Wan, Siyi Xiong, Chengfang Wang, Yuqin Zhou, Dandan Ma, Yangqiu Bao, Man Qu, Jun Jiang, Yi Zhang, Xiaowei Qi
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study. BMC medicine 22 (1) (2024)
Cheng Wang, Long Yuan, Xiujuan Wu, Yan Wang, Hao Tian, Guozhi Zhang, Andi Wan, Siyi Xiong, Chengfang Wang, Yuqin Zhou, Dandan Ma, Yangqiu Bao, Man Qu, Jun Jiang, Yi Zhang, Xiaowei Qi
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study. BMC medicine 22 (1) (2024)
Na Sun, Cheng Wang, Pingping Gao, Rui Wang, Yi Zhang, Xiaowei Qi
Multifaceted roles and functions of SOX30 in human cancer. Cancer innovation 3 (2) (2024)
Na Sun, Cheng Wang, Pingping Gao, Rui Wang, Yi Zhang, Xiaowei Qi
Multifaceted roles and functions of SOX30 in human cancer. Cancer innovation 3 (2) (2024)
Hao Tian, Man Qu, Guozhi Zhang, Long Yuan, Qiyun Shi, Yinhuan Wang, Ying Yang, Yi Zhang, Xiaowei Qi
Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations. The oncologist (2023)
Pingping Gao, Na Sun, Tingting Zhao, Yuanyuan Sun, Jing Gu, Dandan Ma, Hao Tian, Zaihui Peng, Yi Zhang, Fei Han, Xiaowei Qi
Identification of prognostic indicators, diagnostic markers, and possible therapeutic targets among LIM homeobox transcription factors in breast cancer. Cancer innovation 1 (3) (2022)
Qiyun Shi, Juncheng Xuhong, Tao Luo, Jia Ge, Feng Liu, Yang Lan, Qingqiu Chen, Peng Tang, Linjun Fan, Li Chen, Yan Liang, Minghao Wang, Ying Hu, Yi Zhang, Xiu-Wu Bian, Xiaowei Qi, Jun Jiang
PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. British journal of cancer (2022)
Ju Wang, Yanling Li, Wenying Fu, Ye Zhang, Jun Jiang, Yi Zhang, Xiaowei Qi
Prognostic nomogram based on immune scores for breast cancer patients. Cancer medicine 8 (11) (2019)